WELTRUZA Trademark
Trademark Overview
On Thursday, January 15, 2026, a trademark application was filed for WELTRUZA with the United States Patent and Trademark Office. The USPTO has given the WELTRUZA trademark a serial number of 99596389. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Monday, May 25, 2026. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The WELTRUZA trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for the prevention and treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders
General Information
| Serial Number | 99596389 |
| Word Mark | WELTRUZA |
| Filing Date | Thursday, January 15, 2026 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Monday, May 25, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, June 16, 2026 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for the prevention and treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, January 15, 2026 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Teva Pharmaceuticals USA, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Parsippany, NJ 07054
US |
Trademark Events
| Event Date | Event Description |
| Thursday, January 15, 2026 | NEW APPLICATION ENTERED |
| Thursday, January 15, 2026 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, January 15, 2026 | APPLICATION FILING RECEIPT MAILED |
| Tuesday, February 24, 2026 | ASSIGNED TO EXAMINER |
| Tuesday, March 3, 2026 | NON-FINAL ACTION WRITTEN |
| Tuesday, March 3, 2026 | NON-FINAL ACTION E-MAILED |
| Tuesday, March 3, 2026 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, April 24, 2026 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, April 24, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, April 24, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, May 15, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, June 10, 2026 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
